In a nationwide EHR cohort of over 400,000 U.S. infants during the 2024–2025 RSV season, nirsevimab use was linked to a 77% lower risk of RSV-related hospitalization. The study also found reduced ICU admissions and intubations, supporting broad seasonal protection in routine care.
from News Medical Medical Research News Feed https://ift.tt/UsjNSRC
0 Comments